ELIAS Cancer Immunotherapy Gives Dogs with Osteosarcoma More Days at Home

Recent advancements in canine cancer treatment offer the potential for better outcomes, especially the advancements in immunotherapy treatments. A discussion of the ELIAS cancer immunotherapy (ECI®) for the treatment of canine osteosarcoma in Clinician's Brief pointed out that "ECI is the only 2-step immunotherapy in veterinary medicine that has the potential to match or exceed the current standard of care while reducing or eliminating the need for chemotherapy." The article, "Osteosarcoma Immunotherapy for More Days at Home," discusses the evidence-based science behind ECI, the potential benefits over chemotherapy, and how referring veterinarians play an active and vital role in the care continuum. Read the full article at Clinician's Brief online.

By |2022-03-16T17:51:21-06:00February 22nd, 2022|Blog|0 Comments

Canine Cancer Continuum | Part 3: How Immunotherapy Works and Why It’s So Effective

In this final installment of the Canine Cancer Continuum, we talk about immunotherapy - what it is, how it works, and how it can help in the fight against cancer. (Check out Part 1 and Part 2.) “Without an immune system, we would have no way to fight harmful things that enter our body from the outside or harmful changes that occur inside our body. The main tasks of the body’s immune system are: to fight disease-causing germs (pathogens) like bacteria, viruses, parasites or fungi, and to remove them from the body, to recognize and neutralize harmful substances from the environment, and to fight disease-causing changes in the body, such as cancer cells.” (National Institutes of Health) In a nutshell, our immune systems are powerful mechanisms designed to protect us and keep us healthy. They work 24/7 to fight off external threats, like viruses and environmental stressors, and internal threats, like stresses to normal [...]

By |2022-05-30T12:06:05-06:00February 4th, 2022|Blog|0 Comments

Canine Cancer Continuum | Part 2: The Connection Between Canine and Human Cancer

We’re halfway through a series exploring canine cancer. Last week, we discussed the prevalence of dog cancer, and today we will explore the connection between it and human cancer. Human cancer research is extensive. Almost anyone I encounter has either battled cancer themselves or has journeyed that path with someone close to them. Many people are surprised to learn that one in four dogs are diagnosed with cancer and that it’s the leading cause of death in canines. ELIAS Animal Health applies the advancements in human immunotherapy to dogs. They’re good models. From a scientific perspective, we are able to gather data more quickly than in human research because dogs have a shorter lifespan and cancer progresses more quickly in them. From a “we love our furry friends” perspective, we want to bring needed therapies into the veterinary marketplace that help people. ELIAS Cancer Therapies Are Being Simultaneously Developed for Humans [...]

By |2022-05-30T12:14:05-06:00January 27th, 2022|Blog|0 Comments

Canine Cancer Continuum | Part 1: The Prevalence of Dog Cancer

We’re embarking on a 3-part series that explores dog cancer, how our research and progress can be applied to humans, what immunotherapy is, and why it can be so effective. “Cancer is the leading cause of death in dogs and as a rank order, higher than people…” - Dr. Doug Thamm Dogs live in the same environments as humans, exposed to the carcinogens that their owners are. It’s not surprising, then, that one in four dogs is diagnosed with cancer, and it’s the leading cause of death in pets beyond middle age (Veterinary Cancer Society). Dogs experience cancer at rates that are comparable to or exceed those in humans. Canine cancer has primarily been treated the same way for decades - with chemotherapy. Dr. Carolyn Henry, Dean of the University of Missouri College of Veterinary Medicine, has said she is “frustrated by the fact that we don’t see many new therapies coming [...]

By |2022-05-30T12:01:26-06:00January 20th, 2022|Blog|0 Comments

ELIAS Animal Health In-Licenses Oncolytic Vaccinia Virus Treatment for Pet Animals from Genelux Corporation

Agreement grants ELIAS Animal Health the worldwide right to development and commercialization of V-VET1 for the diagnosis, prevention and treatment of cancer in veterinary medicine Nov. 18, 2021 -- Genelux Corporation, a clinical-stage immunotherapy company, recently announced a licensing agreement with ELIAS Animal Health for V-VET1, its clinical-stage animal health product candidate. V-VET1 is a vaccinia viral strain which selectively replicates in cancer cells causing cell death (apoptosis). ELIAS Animal Health is planning clinical trials to evaluate and develop V-VET1 as a potential new immunotherapy option for veterinary oncologists. “We are thrilled to announce our exclusive license for V-VET1 to help veterinarians treat the many pets who are diagnosed with cancer every year,” said Tammie Wahaus, CEO of ELIAS Animal Health. “Companion animal cancer treatments have made little progress in the past few decades, and this partnership is an exciting step in broadening the cancer treatment options available in veterinary medicine.” [...]

By |2022-01-08T14:32:44-06:00November 18th, 2021|News|0 Comments

Clinical study results demonstrate long term survival in dogs with osteosarcoma treated with ELIAS cancer immunotherapy

Results of a clinical study of the ELIAS cancer immunotherapy (ECI®) protocol demonstrated that the administration of an autologous cancer cell vaccination, adoptive T cell transfer, and interleukin‐2 resulted in long‐term survival for dogs with osteosarcoma, a deadly form of bone cancer. The article, published in the Journal of Veterinary Internal Medicine by researchers from the University of Missouri, describes the 14-dog single-arm prospective study and discusses the results. The objective of the study was to evaluate the hypothesis that dogs could be treated safely with the ECI protocol, which includes administration of ex vivo activated T cells, and experience survival times twice that of amputation alone. Median survival time for dogs in the study was 415 days, with one dog developing metastasis then experiencing spontaneous complete remission. Read the full study results. In May, ELIAS Animal Health announced the initiation of a follow-up study to pursue licensure of ECI [...]

By |2020-07-27T10:26:01-06:00July 14th, 2020|News|0 Comments

ELIAS Animal Health announces clinical trial launch: ECI-OSA-04 for the treatment of canine osteosarcoma

Olathe, Kan., May 28, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a follow-up study to pursue licensure of the ELIAS cancer immunotherapy (ECI®) treatment combined with surgery as an alternative to chemotherapy for dogs diagnosed with osteosarcoma, a deadly form of bone cancer. In a preliminary clinical study, the median survival time was 415 days, compared to 270-300 days for traditional chemotherapy treatments, suggesting that ECI holds the potential to significantly improve survival times and quality of life for the canine patient. This clinical trial will enroll dogs that have been diagnosed with osteosarcoma, but have not yet been treated for their cancer. It will be a two-arm study with a 1:1 randomization comparing ECI and carboplatin, a type of chemotherapy. ELIAS is providing financial assistance that will substantially cover costs of participation and treatment [...]

By |2020-06-16T10:15:26-06:00May 28th, 2020|News|0 Comments

ELIAS Animal Health Clinical Dataset Supports FDA Fast Track Designation for TVAX Biomedical

Exciting progress in the fight against cancer for both pets and humans On April 27, the US Food and Drug Administration (FDA) approved the application by our development partner, TVAX Biomedical, for Fast Track Designation for treatment of glioblastoma multiforme (GBM) with the immunotherapy technology ELIAS Animal Health is also using for treatment of osteosarcoma in dogs. Founded on the principle of translational medicine, ELIAS is especially pleased to have supported this major achievement. The efficacy and safety data from the previously completed canine osteosarcoma study conducted by ELIAS was an important component of the TVAX Fast Track application and we are pleased that the results of that study contributed to the FDA’s approval of the GBM Fast Track application. This is a significant accomplishment in that Fast Track Designation is not easily granted by the FDA and requires TVAX to provide evidence of its ability to successfully treat a [...]

By |2020-05-05T07:39:44-06:00May 5th, 2020|News|0 Comments

ELIAS Animal Health and BodeVet announce new collaboration

Olathe, Kan., June 6, 2019 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, and BodeVet, a Maryland-based company focused on the development of novel blood products for use in veterinary transfusion and regenerative medicine, have announced a joint effort to significantly expand the availability of ELIAS’ ECI® treatment for canine cancer via the mobile apheresis capabilities of BodeVet. Apheresis is a processing procedure that separates blood into different components and, in this case, yields the T cells critical to the ELIAS treatment protocol. Currently, there are twelve locations offering apheresis for pets. BodeVet offers a mobile service that will enable veterinary oncologists in most major cities in the United States to incorporate ECI® into their specialty hospital portfolio of oncology services, expanding beyond chemotherapy and radiation. Working together, ELIAS and BodeVet are committed to promoting animal health and welfare by developing [...]

By |2020-02-26T15:07:39-06:00June 6th, 2019|Press Releases|0 Comments
Go to Top